ITT Inc. ITT
Composite 45/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 28/100 — a moderate mark against it.
Momentum ranks 54/100 — a slight point in its favour. Balance-sheet strength ranks 53/100 — a slight point in its favour. Growth ranks 51/100 — a slight point in its favour.
Valuation ranks 28/100 — a moderate mark against it. Quality ranks 45/100 — a slight mark against it. Income ranks 46/100 — a slight mark against it.
What the company does ITT Inc. designs and manufactures engineered critical components and customized technology solutions for transportation, industrial, and energy markets. Its three segments—Motion Technologies, Industrial Process, and Connect & Control Technologies—serve automotive, aerospace, chemical, and power generation industries.
Key financials ITT’s trailing P/E is 34.48 (forward 25.13), PEG 2.03 (forward 0.67), and EV/EBITDA 24.28. Margins include gross 35.4%, operating 16.9%, and net 10.8%. ROE is 12.3%, ROA 6.0%, and ROCE 7.6%. Revenue grew 33% while EPS fell -33%.
Stock health Sideravia scores ITT 44/100 (Average quality, richly valued). Quality 45.5, Growth 39.3, Strength 57.8, Valuation 26.5, Momentum 49.1, Income 50.7. Piotroski F-Score 6/9, Altman Z 2.69, debt/equity 0.84.
Price vs fair value ITT trades at a PREMIUM of 28.60% versus our fair-value estimate of 137.88 and at a discount of 26.94% to the 12-month target of 245.00. - Analysts expect earnings growth ahead of next week’s release (Zacks) - Simply Wall St highlights valuation attention amid recent pullback - Carlisle’s Q2 beat may reflect sector momentum (Zacks)
Looking forward Forward P/E of 25.13 and PEG of 0.67 suggest potential re-rating if execution improves. Revenue growth of 33% supports optimism, but EPS contraction (-33%) and high multiples cap near-term upside.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.